Clinical Trial Update: PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating the combination of a PD-1 inhibitor with venetoclax and the CAG regimen for relapsed/refractory T-cell acute lymphoblas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Aclarubicin (aclarubicin)
• CYTARABINE (CYTARABINE)
• Filgrastim (filgrastim)
• PD-1 inhibitor (unspecified)
• Venetoclax (venetoclax)

Snippet

Sponsor: Fujian Medical University Union Hospital | Conditions: Acute T Lymphoblastic Leukemia (T-ALL) | Phase 3 | Status: ACTIVE_NOT_RECRUITING